Brief: Greenwich LifeSciences Provides Updates On Flamingo-01 Phase III Clinical Trial
03/08/2022 13:15
Aug 3 (Reuters) - Greenwich LifeSciences Inc GLSI.O :
* GREENWICH LIFESCIENCES PROVIDES UPDATES ON FLAMINGO-01
PHASE III
CLINICAL TRIAL
* GREENWICH LIFESCIENCES PROVIDES UPDATES ON FLAMINGO-01
PHASE III
CLINICAL TRIAL
* GREENWICH LIFESCIENCES INC - CONTINUE TO ACTIVELY RECRUIT
AND
PREPARE ADDITIONAL US CLINICAL SITES
* GREENWICH LIFESCIENCES INC - CONTINUING TO MAKE PROGRESS
TO
INITIATE CLINICAL SITES IN EUROPE
Source text for Eikon: ID:nBw9v8zRNa
Further company coverage: GLSI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Greenwich Lifesciences
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Greenwich Lifesciences Inc reports results for the quarter ended June 30 - Earnings Summary
Greenwich Lifesciences Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: Greenwich Lifesciences Announces Approval To Expand FLAMINGO-01 Into The United Kingdom
U.S. STOCKS ON THE MOVE-Yum Brands, AMD, Nuvation Bio